Greenwich Wealth Management LLC Purchases 653 Shares of Novartis AG (NYSE:NVS)

Greenwich Wealth Management LLC raised its position in shares of Novartis AG (NYSE:NVS) by 5.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,378 shares of the company’s stock after purchasing an additional 653 shares during the quarter. Greenwich Wealth Management LLC’s holdings in Novartis were worth $1,205,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Legacy Investment Solutions LLC bought a new stake in shares of Novartis during the 3rd quarter valued at about $28,000. Human Investing LLC bought a new position in shares of Novartis during the 4th quarter valued at approximately $25,000. Union Bancaire Privee UBP SA bought a new position in shares of Novartis during the 4th quarter valued at approximately $27,000. Kestra Investment Management LLC bought a new position in shares of Novartis during the 4th quarter valued at approximately $47,000. Finally, Clearstead Trust LLC bought a new position in shares of Novartis during the 4th quarter valued at approximately $51,000. 13.12% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NVS. Deutsche Bank Aktiengesellschaft upgraded Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. Morgan Stanley began coverage on Novartis in a research note on Wednesday, February 12th. They set an “underweight” rating for the company. StockNews.com upgraded Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 8th. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. Finally, HSBC cut Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Novartis has a consensus rating of “Hold” and an average price target of $123.38.

Novartis Stock Up 0.0 %

Shares of NVS opened at $109.15 on Friday. The stock has a market capitalization of $223.10 billion, a price-to-earnings ratio of 18.56, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92. The business’s 50 day simple moving average is $105.36 and its 200-day simple moving average is $107.68. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. As a group, equities analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Dividend Announcement

The business also recently announced a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were given a dividend of $3.8695 per share. The ex-dividend date was Wednesday, March 12th. Novartis’s dividend payout ratio is currently 42.69%.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.